Biotech has seen a surge in the development of new modalities in recent years. At a16z bio+health, we spend a lot of time thinking about how new modalities fit into increasingly crowded indication landscapes.
Join us in welcoming Dr. Greg Verdine as a16z Bio + Health Venture Partner!
With a record of academic leadership, innovative drug discovery & serial entrepreneurial success in biotech, he's a game-changer.
More from @vintweeta + @JorgeCondeBio here: a16z.com/2023/07/20/gre…
Thrilled to be part of this years team and the opportunity to make an impact on such an important cause! Please consider donating: justgiving.com/fundraising/be…
1/ "In the history of medicine, certain therapeutic classes have revolutionized the treatment of both prevalent and rare diseases, and RNA-based therapeutics is undoubtedly one of them.”
-- @gciaramella1
Excited for the launch of Orbital Tx today! businesswire.com/news/home/2022…